PTC Therapeutics Q4 2022 Earnings Report
Key Takeaways
PTC Therapeutics reported total revenues of $167.4 million for the fourth quarter of 2022, compared to $165.2 million for the fourth quarter of 2021. The company's total revenues for the full year 2022 were $698.8 million, compared to $538.6 million for the full year 2021. PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion.
Total revenues were $167.4 million for the fourth quarter of 2022.
Net product revenue across the commercial portfolio was $127.5 million for the fourth quarter of 2022.
GAAP R&D expenses were $188.7 million for the fourth quarter of 2022.
Net loss was $170.9 million for the fourth quarter of 2022.
PTC Therapeutics
PTC Therapeutics
PTC Therapeutics Revenue by Segment
Forward Guidance
PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income